(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
7 June 2012 (07.06.2012)

WIPO | PCT

(10) International Publication Number
WO 2012/074761 A1

(51) International Patent Classification:
C07D 498/04 (2006.01) *A61P 35/00* (2006.01)
A61K 31/424 (2006.01)

(21) International Application Number:
PCT/US2011/061099

(22) International Filing Date:
17 November 2011 (17.11.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10382329.0 3 December 2010 (03.12.2010) EP
61/439,151 3 February 2011 (03.02.2011) US

(71) Applicant *(for all designated States except US)*: **ELI LILLY AND COMPANY** [US/US]; Lilly Corporate Center, Indianapolis, Indiana 46285 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **COATES, David, Andrew** [US/US]; c/o Eli Lilly and Company, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). **GILMOUR, Raymond** [GB/US]; c/o Eli Lilly and Company, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). **MARTIN, Jose, Alfredo** [ES/ES]; c/o Eli Lilly and Company, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). **MARTIN DE LA NAVA, Eva, Maria** [ES/ES]; c/o Eli Lilly and Company, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US).

(74) Agents: **TUCKER, Tina M.** et al.; Eli Lilly And Company, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

WO 2012/074761 A1

(54) Title: OXAZOLO [5, 4 -B] PYRIDIN- 5 -YL COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CANCER

(57) Abstract: The present invention provides oxazolo[5,4-b]pyridin-5-yl compounds useful in the treatment of cancer.